Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Cobimetinib + Vemurafenib |
| Indication/Tumor Type | salivary gland carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | salivary gland carcinoma | predicted - sensitive | Cobimetinib + Vemurafenib | Case Reports/Case Series | Actionable | In a clinical case study, real-world treatment with the combination of Zelboraf (vemurafenib) and Cotellic (cobimetinib) resulted in 1 complete response and 2 partial responses in 3 patients with salivary duct carcinoma harboring BRAF V600E (PMID: 42066686). | 42066686 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (42066686) | Real-world effectiveness of molecular-matched therapies in salivary gland cancer. | Full reference... |